The customary approach to early-phase clinical trial design, where the focus is on identification of the maximum tolerated dose, is not always suitable for noncytotoxic or other targeted therapies.
Zachary del Rosario has received funding from the National Science Foundation and Toyota Research Institute. Probability underpins AI, cryptography and statistics. However, as the philosopher Bertrand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results